The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Part of the market evolution in the glucagon space involves the shift to ready-to-use products such as BAQSIMI which we believe positions us to seize new opportunities in the coming year.

Gvoke is the second new glucagon product to be registered in the US in the last few weeks. Towards the end of July, the FDA approved Eli Lilly’s intranasal formulation of the drug, Baqsimi ...

Furthermore, BAQSIMI showed strong factory sales growth ... including a competitive approval for glucagon (~15% of Amphastar revenues) and several pipeline delays. Analyst Ekaterina Knyazkova ...